Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
|Articles|August 15, 2014
- BioPharm International-08-15-2014
- Volume 2014 eBook
- Issue 2
Testing the Quality, Safety, and Efficacy of Insulin Biosimilars
Development and validation of two pivotal assays for in-vitro comparability testing of insulin biosimilars.
Advertisement
Development and validation of two pivotal assays for in-vitro comparability testing of insulin biosimilars.
from BioPharm International’s 2014 Analytical and Bioanalytical eBook.
Articles in this issue
about 12 years ago
Keys to Successful Method Transferabout 12 years ago
The Challenge of Finding the Unknownabout 12 years ago
Using the Purity Quotient Difference to Assess Protein Purificationabout 12 years ago
Standardizing Data ManagementAdvertisement
Related to this article
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
5